Myeloproliferative Neoplasms News

In 1984, a teenage boy was lying in his hospital bed, his body ravaged by acute graft-versus host disease.

Since having the good fortune to take on an editorial role for HemOnc Today, I have resisted the temptation to use the January editorial to provide a summary of highlights from ASH Annual Meeting and Exposition, or to enter the “reflective zone” at the turn of the year. Both seem a little predictable and formulaic.

Luspatercept reduced the severity of anemia compared with placebo among certain patients with lower-risk myelodysplastic syndromes, according to results of a randomized phase 3 trial published in The New England Journal of Medicine.

The FDA granted orphan drug designation to PRGN-3006 for the treatment of relapsed or refractory acute myeloid leukemia, according to the agent’s manufacturer.

American Association for Cancer Research and MPM Capital awarded two grants that will provide a combined $800,000 for cancer research.

ASH announced the recipients of its 2019 Scholar Awards.

Older patients with myelodysplastic syndrome appeared more likely to receive persistent treatment with hypomethylating agents under the care of more experienced providers of the agents, according to results of a population-based analysis published in Leukemia & Lymphoma.

An oral chemotherapy treatment used to treat myeloproliferative neoplasms is associated with substantial weight gain and increased systolic blood pressure, according to findings from a real-world analysis published in Scientific Reports.

Patients with polycythemia vera can experience high symptom burden even if their blood counts are controlled, according to an analysis from the prospective, observational REVEAL study.

The FDA office that reviews applications for cancer therapies has been renamed and reorganized.